LGND (Ligand Pharmaceuticals Incorporated) Prakiraan pendapatan perusahaan

Ligand (LGND) - logo korporat

The investment attractiveness of Ligand Pharmaceuticals (LGND) is based on stable royalties from an extensive patent portfolio. The company's projected sales dynamics clearly confirm this trend, where this metric equals 1.19. Its status as a reliable partner for leading laboratories and unique methods for increasing molecular solubility strengthen the brand's position, while strict FDA oversight and the complexity of replicating Captisol technologies create an insurmountable barrier to entry for competitors.

LGND - Dodolan mangsa ngarep perusahaan Ligand Corp ing rentang 04.07.2022 - 18.11.2026

Rincian analitis perusahaan Ligand Pharmaceuticals

- nilai saham lan prakiraan konsensus rega:
Ringkesan analitik perusahaan:Ligand Pharma
Produk merek Ligand Pharma

The market assesses the investment potential of Ligand Pharmaceuticals (LGND) as moderately risky, given the current value of 1.19. This metric aggregates expected shipment volumes considering global market transformations; therefore, the projected sales trajectory reflects the sensitivity of royalties to the commercial success of partners and regulatory pressure in the US, determining the fundamental value of this biopharmaceutical asset.

Karo sapa Ligand Pharmaceuticals saingan

Prakiraan volume dodolan HLN|KVUE (Kenvue Inc) - Pendapatan mangsa ngarep perusahaan|Verona Pharma Corp - Volume dodolan mangsa ngarep perusahaan|Prakiraan volume pendapatan perusahaan MENS (Jyong Biotech Ltd)|AMRX - Prakiraan pendapatan perusahaan|Volume dodolan sing dikarepake perusahaan perrigo.com|ALVO (Alvotech SA) - Volume dodolan mangsa ngarep perusahaan|Prakiraan dodolan perusahaan Liquidia Technologies LQDA|GLPG (Galapagos N.V.) - Prakiraan volume dodolan|ANIP: Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan Afrezza (MNKD)|Prakiraan volume dodolan amphastar.com (AMPH)|Prakiraan volume dodolan PCRX (pacira.com)|Pendapatan mangsa ngarep perusahaan SPRY|Theravance Biopharma Inc - Prakiraan volume dodolan|Dodolan mangsa ngarep perusahaan Aquestive Therapeutics AQST|SCPH: Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan Tectonic Therapeutic, Inc.|TNXP (tonixpharma.com) - Prakiraan volume dodolan|SXTC (China SXT Pharmaceuticals, Inc.) - Prakiraan volume pendapatan perusahaan|Prakiraan pendapatan perusahaan eupraxiapharma.com (EPRX)|Prakiraan volume pendapatan perusahaan BHST|Prakiraan pendapatan perusahaan eXoZymes EXOZ|Pendapatan mangsa ngarep perusahaan ORMP|ENTX - Prakiraan pendapatan perusahaan|HYFT: Prakiraan pendapatan perusahaan|ABVC BioPharma, Inc (ABVC) - Prakiraan pendapatan perusahaan|Cumberland Pharma - Pendapatan mangsa ngarep perusahaan|QNTM (Quantum BioPharma Corp) - Prakiraan volume dodolan|FibroGen, Inc. - Pendapatan sing dikarepake perusahaan|Prakiraan volume dodolan TELO|Dodolan mangsa ngarep perusahaan Rani Therapeutics Holdings, Inc.|Prakiraan pendapatan perusahaan Synergy CHC Corp. SNYR|Prakiraan volume dodolan rallybio.com RLYB|Lexaria Bioscience Corp. - Prakiraan volume dodolan|PULM: Prakiraan pendapatan perusahaan|PTHL (ftzy.com.cn) - Volume dodolan mangsa ngarep perusahaan|APM: Prakiraan volume pendapatan perusahaan|LYRA (Lyra Therapeutics Inc) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan IBO (Impact BioMedical)|Volume dodolan mangsa ngarep perusahaan TNFA (TNF Pharmaceuticals)|Prakiraan volume dodolan cbdMD Corp (YCBD)|Prakiraan volume dodolan PRFX (PainReform)|Dodolan mangsa ngarep perusahaan Auris Medical (CYTO)|LIPO - Prakiraan pendapatan perusahaan|Optinose (OPTN) - Volume dodolan mangsa ngarep perusahaan|Pieris (PIRS) - Prakiraan pendapatan perusahaan|Pendapatan sing dikarepake perusahaan PROC (Procaps Group S.A.)|Volume dodolan mangsa ngarep perusahaan PTPI|QLI: Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan acelyrin.com (SLRN)|TFFP (TFF Pharma) - Pendapatan mangsa ngarep perusahaan